Trials / Unknown
UnknownNCT04825392
A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
A Phase Ib Study of Tolerance and Safety of a Recombinant Anti-PD-1 Monoclonal Antibody HX008 in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Taizhou Hanzhong biomedical co. LTD · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
HX008 is a humanized monoclonal antibody targeting PD-1 on the T cell surface, restores T cell activity, thus enhancing immune response, and has the potential to treat various types of tumors. In this study, the tolerance and safety of HX008 in patients with advanced solid tumors will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HX008 | Patients will receive HX008 3mg/kg by intravenous (IV) infusion on Day 1, every 3 weeks (Q3W), till progressed disease or withdrawal. |
Timeline
- Start date
- 2019-09-05
- Primary completion
- 2021-05-30
- Completion
- 2021-12-30
- First posted
- 2021-04-01
- Last updated
- 2021-04-01
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04825392. Inclusion in this directory is not an endorsement.